<DOC>
	<DOCNO>NCT01918878</DOCNO>
	<brief_summary>This prospective , multicenter , single arm study . The study group compose NVAMD patient partial complete failure respond initial bevacizumab ranibizumab treatment 3-6 monthly intravitreal injection . The patient study group receive 5 intravitreal injection aflibercept 2mg/0.05ml specific visit . Aflibercept provide total period 24 week .</brief_summary>
	<brief_title>Aflibercept ( EYLEA ) Secondary Third Line Treatment Neovascular Age-related Macular Degeneration .</brief_title>
	<detailed_description>The aim study prospectively evaluate use aflibercept patient initial incomplete response loss initial response intravitreal anti- vascular endothelial growth factor ( anti-VEGF ) therapy demonstrate . This multi-center study initiate conduct Israeli retina association . Each center participate study follow protocol include standardized measurement visual acuity , OCT , Fluorescein angiography ( FA ) . We enroll 48 NVAMD patient partial non-responded 3-6 injection intravitreal bevacizumab ranibizumab one year treatment . Test Treatment : Monthly intravitreal aflibercept 2mg /0.05 ml give enrolment ( day 0 ) , 4 week , 8 week , 16 week , 24 week initial enrollment study group . Follow-up period 28 weeks,7 visit . At 28 week visit primary secondary end point evaluate .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>Ophthalmic Inclusion Criteria 1 . Failure previous intravitreal bevacizumab ranibizumab treatment , define : 36 intravitreal injection ( The last 3 injection must 6 week one injection another ) . Maximal central thickness Heidelberg OCT least 300 micron large ( retinal thickness include subretinal fluid { SRF } , intraretinal fluid { IRF } PED ) . 2 . Subfoveal choroidal neovascularization ( CNV ) due AMD document fluorescein angiogram . 3 . Best correct visual acuity study eye 20/40 20/360 , inclusive . The VA must reconfirm Day 0 prior initiation treatment . 4 . Total area lesion ( include blood , neovascularization , scar/atrophy ) must ≤ 5 disc area ( DA ) , least 50 % must active CNV . Active CNV define neovascular component lesion define fluorescein angiogram . 5 . Presence OCT subretinal , intraretinal subretinal pigment epithelial ( RPE ) fluid and/or subretinal thickening consistent active CNV . 6 . Clear ocular medium adequate pupillary dilatation 7 . Intraocular pressure ( IOP ) 21 mmHg less . General Inclusion Criteria 1 . Subjects either gender , age 50 year . 2 . Women postmenopausal least 12 month prior trial entry , surgically sterile . 3 . Provide write informed consent . 4 . Ability comply study followup procedure return trial visit . Ophthalmic Exclusion Criteria 1 . More 50 % total lesion size consist subretinal hemorrhage . 2 . Presence retinal angiomatous proliferation ( RAP ) . 3 . Presence pigment epithelial tear . 4 . Hypersensitivity active substance aflibercept excipients . 5 . Active suspect ocular periocular infection . 6 . Active severe intraocular inflammation ( ≥ trace cell flare ) , significant epiretinal membrane vitreomacular traction , macular hole vitreous hemorrhage . 7 . Aphakia absence posterior capsule . Absence intact posterior capsule allow occur result YAG laser posterior capsulotomy association prior posterior chamber intraocular lens ( IOL ) implantation . 8 . History idiopathic autoimmuneassociated uveitis either eye . 9 . Significant medium opacity , include cataract , might interfere visual acuity , assessment toxicity , fundus photography study eye . Subjects enter likelihood require cataract surgery study eye next 7 month . 10 . Presence cause choroidal neovascularization , include pathologic myopia ( spherical equivalent 8 diopter ) , ocular histoplasmosis syndrome , angioid streak , choroidal rupture , multifocal choroiditis . 11 . Any intraocular surgery thermal laser within three ( 3 ) month trial entry . 12 . History follow condition procedure study eye : rhegmatogenous retinal detachment , par plana vitrectomy , filter surgery ( e.g . trabeculectomy ) , glaucoma drainage device , corneal transplant . 13 . Previous therapeutic radiation region study eye . General Exclusion Criteria 1 . Any following underlying disease include : 1 . Clinically significant impaired renal ( serum creatinine &gt; 2.5 mg/dl s/p renal transplant receive dialysis ) hepatic function . 2 . Stroke ( within 3 month trial entry ) . 3 . Any major surgical procedure within one month trial entry . 2 . Any treatment investigational agent 60 day prior trial entry condition . 3 . Known serious allergy fluorescein dye use angiography ( mild allergy amenable treatment allowable ) , component bevacizumab , aflibercept formulation . 4 . Women childbearing potential .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>age-related macular degeneration</keyword>
	<keyword>intravitreal injection</keyword>
	<keyword>Aflibercept</keyword>
	<keyword>EYLEA</keyword>
</DOC>